For years, relapse after initial therapy has defined the outlook for people with extensive-stage small cell lung cancer (ES-SCLC). The FDA approval of a first-line maintenance combination regimen marks an important step forward, building on past progress and creating the possibility of longer-lasting benefit for patients and families. People with sleep conditions, such as narcolepsy and idiopathic hypersomnia, have an increased prevalence of cardiovascular comorbidities compared to people without these sleep conditions. At Jazz, we aim to raise awareness of these connections through our research and partnerships with the goal of providing patients and healthcare providers with meaningful insights that can impact their lives. As we deepen our commitment to oncology, we’re focused on bringing forward meaningful innovation for patients, especially those facing rare and aggressive cancers like H3 K27M-mutant diffuse midline glioma. With the FDA approval of the first treatment for this cancer, there is new hope for patients and families who are navigating this life-threatening disease.
Transforming Lives.
Redefining Possibilities.
Perspectives
Moving the Needle in First-Line Maintenance Therapy for Small Cell Lung Cancer Care
Science Stories
Understanding the Connection Between Sleep, Heart Health and Sodium Intake
Science Stories
A Turning Point in H3 K27M-mutant Diffuse Midline Glioma
News and Events
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
Living Our Values
Clinical Trials
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.